This trial is active, not recruiting.

Condition sarcoma
Treatments temozolomide, thalidomide
Phase phase 2
Sponsor Herbert Irving Comprehensive Cancer Center
Collaborator National Cancer Institute (NCI)
Start date March 2002
Trial identifier NCT00033709, CDR0000069314, CPMC-IRB-14323, NCI-G02-2060


RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Combining temozolomide with thalidomide may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combining temozolomide with thalidomide in treating patients who have metastatic, locally advanced, or unresectable leiomyosarcoma.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Primary purpose treatment

Primary Outcomes

Response (complete and partial response)
time frame:

Secondary Outcomes

Time to progression
time frame:
Overall survival
time frame:
Clinical benefit
time frame:

Eligibility Criteria

Male or female participants at least 18 years old.

DISEASE CHARACTERISTICS: - Histologically confirmed leiomyosarcoma - Metastatic, locally advanced, or unresectable - Ineligible for other high priority national or institutional study - At least 1 unidimensionally measurable lesion documented on radiologic study - At least 2 cm by 2 cm - Not previously irradiated unless disease progression at the site is evident - No brain metastases PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - SWOG 0-2 Life expectancy: - More than 2 months Hematopoietic: - WBC greater than 3,000/mm^3 - Neutrophil count at least 1,500/mm^3 - Platelet count greater than 70,000/mm^3 - Hemoglobin at least 10 g/dL Hepatic: - Bilirubin less than upper limit of normal (ULN) - SGOT or SGPT less than 1.5 times ULN* - Alkaline phosphatase less than 2 times ULN* NOTE: * Less than 5 times ULN if documented liver disease Renal: - Creatinine less than 1.5 times normal OR - Creatinine clearance greater than 60 mL/min - BUN less than 1.5 times normal Other: - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use 2 forms of effective contraception for 4 weeks before, during, and for 4 weeks after study therapy - No acute infection requiring systemic antibiotics - No frequent vomiting or medical condition that would preclude intake of oral medication (e.g., partial bowel obstruction) - No other serious medical or psychiatric illness that would preclude study participation - No prior malignancy except curatively treated carcinoma in situ of the cervix or skin cancer PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - At least 4 weeks since prior chemotherapy - No more than 3 prior systemic chemotherapy regimens for metastatic, locally advanced, or unresectable leiomyosarcoma - Prior dacarbazine allowed Endocrine therapy: - Not specified Radiotherapy: - See Disease Characteristics - At least 4 weeks since prior radiotherapy - No prior radiotherapy to 50% or more of bone marrow - Concurrent radiotherapy for local control or palliative therapy for painful bony or soft tissue lesion allowed Surgery: - At least 4 weeks since prior surgery and recovered Other: - Recovered from all prior therapies - No other concurrent investigational drugs

Additional Information

Official title A Phase II Study of Combination Therapy of a Protracted Oral Schedule of Temozolomide and Thalidomide as First-Line or Subsequent Therapy for Patients With Metastatic, Locally Advanced or Unresectable Leiomyosarcoma
Description OBJECTIVES: - Determine the efficacy of temozolomide and thalidomide in patients with metastatic, locally advanced, or unresectable leiomyosarcoma. - Determine the time to progression in patients treated with this regimen. - Determine the overall survival of patients treated with this regimen. - Determine the clinical and laboratory toxic effects and tolerability of this regimen in these patients. OUTLINE: Patients receive oral temozolomide once daily for 7 days every other week and oral thalidomide once daily. Treatment continues for up to 26 weeks in the absence of disease progression or unacceptable toxicity. PROJECTED ACCRUAL: A total of 15-25 patients will be accrued for this study within 7.5-25 months.
Trial information was received from ClinicalTrials.gov and was last updated in January 2014.
Information provided to ClinicalTrials.gov by National Cancer Institute (NCI).